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Rilpivirine (RPV) is a pharmaceutical drug used for the treatment of HIV infection. The drug
is characterized with poor aqueous solubility and dissolution rate leading to low
bioavailability of the drug. Hence, there is a need for the improvement of the solubility and
dissolution of such drugs. In this exertion, enhancement of the solubility and dissolution of
the practically water insoluble drug rilpivirine was achieved by solid dispersion (SD)
preparation using solvent evaporation method which eventually leads to bioavailability
enhancement. SD's were formed using Kollidon VA 64 which is a water-soluble copolymer
and varying copolymer ratio to Avicel PH-101, Gelucire 50/13 and lecithin soya. Solubility
studies were carried out to establish the solubility-enhancing property of the SD's. To
support solubility analysis results, powder dissolution studies were carried out. The SD's
were characterized by Fourier transform infrared spectroscopy, differential scanning
calorimetry, X-ray powder diffraction studies, scanning electron microscopy. It was found
that the SD's formed showed the absence of crystalline nature of the drug and its con-
version to amorphous state. The solubility and dissolution of the rilpivirine SD's were
enhanced. There is a 14.9 fold increase in solubility for Drug: Kollidan VA 64: Gelucire 50/13
(1:4:1). For Drug: Kollidan VA 64 (1:5), Drug: Kollidan VA 64: Lecithin soya (1:4:1) and Drug:
Kollidan VA 64: Avicel PH-101 (1:4:1) it was 5.9, 5.4 and 4.2 respectively. In-vitro drug release
kinetics was investigated. This study demonstrates the use of solvent evaporation method
for the preparation of SD’S in solubility and dissolution enhancement.
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Rilpivirine, 4-{[4-({4-[(E)-2-cyanovinyl]-2, 6-dimethylphenyl}
amino) pyrimidin-2-yl] amino} benzonitrile is a pharmaceu-
tical drug used for the treatment of HIV infection. It is a
second-generation non-nucleoside reverse transcriptase in-
hibitor (NNRTI) with higher potency, longer half-life and
reduced side-effect profile compared with older NNRTIs, such
as efavirenz (Stellbrink, 2007; Goebel et al., 2006). Although
rilpivirine has gained acceptance in the treatment of HIV
infection, it is characterized with poor solubility which limits
its absorption and dissolution rate which delays onset of ac-
tion (Baert et al., 2009; Sharma and Garg, 2010). The chemical
structure of rilpivirine is shown in Fig. 1.
According to the Biopharmaceutical Classification System
(BCS), most of the drugs exhibiting insolubility belong to BCS
class II. This class includes drugs having low water solubility
with highmembrane permeability. For this reason dissolution
will be the rate-limiting step in drug absorption from the oral
solid dosage forms of this class (Amidon et al., 1995). Current
statistics report that about 40% of new chemical entities
(NCEs) are known to belong to the biopharmaceutics classifi-
cation systems (BCS) class II type of molecules with poor sol-
ubility and high permeability properties (Stegemann et al.,
2007; Amidon et al., 1995). Rilpivirine is classified as a BCS
class II compound (Anita, 2012). Different solubility and
dissolution enhancement techniques are applied such as in-
clusion complexation (Veiga et al., 1996), drug micronization
in to amorphous form (Hancock and Zografi, 1997), prodrug
formation (Rautio et al., 2008) and solid dispersion (Porter
et al., 2008; Vasconcelos et al., 2007; Chiou and Riegelman,
1971; Serajuddin, 1999; Leuner and Dressman, 2000). Among
these methods, solid dispersion technique is most frequently
used.
Solvent evaporation method involves preparation of a
solution containing both matrix material and drug, and the
removal of the solvent resulting in the formation of the solid
mass. Nature of the solvent and the rate of evaporation of
the solvent are the critical factors which can affect the
formed mass (Xie et al., 2009). The most important advan-
tage of this method is that thermal decomposition of the
drugs can be avoided as low temperature is required for theFig. 1 e Chemical structure of Rilpivirine.evaporation of the organic solvents. Preparation of solid
dispersions using solvent evaporation method has been
utilized successfully for the improvement of dissolution rate
and stability of SDs of poor aqueous soluble drugs (Leuner
and Dressman, 2000; Patel and Patel, 2006; Sethia and
Squillante, 2004; Jahan, 2011). In the present study Kollidon
VA 64 which is a water soluble copolymer is used as matrix
material and the solvent system constitutes methanol and
ethanol in the ratio 1:1.
The aim of this workwas to improve the aqueous solubility
and dissolution of rilpivirine using solid dispersion technique
using hydrophilic carrier Kollidon VA 64. Powder X-ray
diffraction (XRD), Fourier transform infrared spectroscopy
(FTIR) and differential scanning calorimetry (DSC) were used
to characterize the solid-state properties of rilpivirine, the
physicalmixture and solid dispersions. The aqueous solubility
and dissolution behaviour of rilpivirine SDs were evaluated
further. Surface morphology study was carried out using
scanning electron microscopy (SEM).2. Materials and methods
2.1. Materials
Rilpivrine (RPV) was a gift from PharmaTrain (Hyderabad,
India). Kollidon VA 64 was procured from BASF (Germany),
Soya lecithin was from VWR International Ltd (Poole, En-
gland), Avicel PH-101 was from SigmaeAldrich (Saint Louis,
USA), Gelucire 50/13 was provided by Gattefosse (Cedex,
France), Ethanol Absolute 99.9% was from Commercial Alco-
hols (Brampton, Canada) and methanol HPLC grade (merck).
All the chemicals usedwere analytical reagent grade and used
without further purification.
2.2. Methods
2.2.1. Preparation of physical mixture
Physicalmixtures (PMs) of RPV in the ratio RPV: Kollidan VA 64
(1:5) (PM1), RPV: Kollidan VA 64: Lecithin soya (1:4:1) (PM2),
RPV: Kollidan VA 64: Avicel PH-101 (1:4:1) (PM3) and RPV:
Kollidan VA 64: Gelucire 50/13 (1:4:1) (PM4) were prepared by
blending them by triturating for about 10 min and sieved
through 500 micron mesh sieve.
2.2.2. Preparation of solid dispersion
SDs of RPV was prepared by solvent evaporation method.
Prepared PMs of RPVwere transferred into a beaker containing
ethanol and methanol in the ratio 1:1. The solvent was then
evaporated under vacuum (Roots vacuum pump-WZJP70,
Hyderabad-india) and the resulting solid dispersions were
collected and stored in desiccators until they attained con-
stant weight. The solidified masses were crushed, pulverized
and passed through size-60 mesh (Retsch, Verder Scientific
India Pvt. e India).
2.2.3. Powder X-ray diffraction (XRD)
The XRD patterns of pure RPV, PMs and all binary systems of
RPV with Kollidan VA 64 were recorded using a Bruker D8
advance X-ray diffractometer (Bruker AXS GmbH, Germany)
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
2q to
45

2q, with step size 0.01

2q and time per step of 0.4 s. The
instrument was operated at 40 kV generator voltage and
40 mA generator current. Variable divergent slit and Anti
scattering slit were used of V20mm, Nickel filter was used in
secondary beam path. Eva software (which is also available in
online version for free) was used for data processing and
evaluation.
2.2.4. Differential scanning calorimetry (DSC)
DSC (Mettler Toledo DSC 831e, Switzerland) with STARe soft-
ware was used for recording and processing DSC thermo-
grams of RPV, PMs and binary systems of RPV with Kollidan
VA 64. The accurately weighed sample (3e5 mg) was placed in
an aluminium pan. An empty aluminium pan was used as a
reference. The experiment was carried out in nitrogen atmo-
sphere at a flow rate 40 mL per min at a scanning rate of
20 C min in the range of 30e350 C.
2.2.5. Fourier transform infrared spectroscopy (FTIR) studies
Infrared spectra were obtained using a PerkineElmer
Spectrum-one FTIR spectrometer (Shelton, CT, USA) using
universal Attenuated Total Reflectance (UATR) accessory. The
scanning range was kept from 4000 to 650 cm1 and the ac-
cumulations were 4.
2.2.6. Scanning electron microscopy (SEM)
The morphology of the RPV and SDs were investigated by
scanning electron microscopy (SEM, JOEL JSM-6380) at an
accelerating voltage of 1.0 kV. Double coated carbon conduc-
tive tabs aremounted on SEM sample stubs and samples were
stick uniformly and coated by Platinum Sputter Coater vac-
uum coater (JEOL, JFC 1600, Auto fine Coater) to minimize
electrostatic charging.
2.2.7. Solubility determination
The equilibrium solubility of the pure drug and the prepared
SDs were determined in Ultra-pure water (Millipore®, USA)
by adding excess amount of sample in water and theFig. 2 e XRD patterns of single components and binary systems o
101 (d), Gelucire 50/13 (e), PM1 (f), PM2 (i), PM3 (g) and PM4 (h).samples were shaken for 24 h at 37 C in a horizontal shaker
(n ¼ 3). After the supernatant is filtered through 0.45 mm
filters the filtrate was assayed spectrophotometrically at
306 nm.
2.2.8. Drug release rate studies
USP apparatus II (paddle) method using electrolab dissolution
apparatus was used to study the drug release profile. Disso-
lution studies were carried out using 900 mL 0.5% Polysorbate
20 in 0.01 N HCl (pH ¼ 2.0) at 37 ± 0.5 C and stirred at 75 rpm.
Amount of samples equivalent to twenty-fivemg of RPV were
added to dissolution medium and Five mL samples were
withdrawn after 10, 20, 30, 45 and 60 min and replaced each
time with 5 mL fresh 0.5% Polysorbate 20 in 0.01 N HCl. The
solutions were immediately filtered through 0.45 mm mem-
brane filter, diluted and the concentration of RPV determined
spectrophotometrically. Different mathematical models
were applied to dissolution data to study the drug release
kinetics.3. Results and discussion
Fig. 2 shows the overlaid XRD patterns of pure RPV (a), Kolli-
dan VA 64 (b), Lecithin soya (c), Avicel PH-101 (d), Gelucire 50/
13 (e) and f, i, g and h represents PMs PM1, PM2, PM3 and PM4
respectively. RPV showed characteristic diffraction peaks at
two theta positions mentioned in Table 1 along with their
d values and peak intensities. From these values it is evident
that input RPV is in crystalline nature. Kollidan VA 64 (b) and
Lecithin soya (c) are amorphous in nature and Avicel PH-101
(d) is crystalline and Gelucire 50/13 (e) is mostly amorphous
in nature. Since the Physical mixtures (PMs) of RPV have no
additional peaks other than RPV and respective constituents
they are compatible. The crystallinity of RPV was significantly
reduced in the physical mixture but to a much greater extent
in the latter, as almost all intense peaks of pure RPV had
completely disappeared. The absence of peaks indicated that
the drugwas uniformly dispersed in thematrixmaterial. Fig. 3f RPV (a) and kollidan VA 64 (b), Lecithin soya (c), Avicel PH-
Table 1 e X-ray diffraction characteristic 2q

peak
positions, d values and intensities of pure rilpivirine
hydrochloride.
Angle (2-Theta

) d value (Angstrom) Intensity (counts)
9.000 9.818 172
9.674 9.135 628
10.777 8.203 197
10.951 8.072 343
13.435 6.585 1843
14.511 6.099 1116
14.959 5.917 1124
15.262 5.800 130
15.999 5.536 193
16.415 5.396 852
14.568 5.346 1043
16.923 5.235 200
17.359 5.104 146
18.061 4.919 393
18.442 4.807 567
19.211 4.616 318
19.380 4.577 385
19.829 4.474 168
20.894 4.248 847
21.077 4.211 2556
21.279 4.172 1348
21.625 4.106 290
21.957 4.044 2275
22.761 3.904 1067
22.986 3.806 586
23.645 3.759 488
24.281 3.663 2657
24.471 3.635 778
25.244 3.566 2259
25.615 3.525 2156
26.333 3.475 1636
27.032 3.381 359
27.182 3.349 1786
27.596 3.295 619
28.752 3.278 687
29.202 3.229 961
29.990 3.102 288
30.940 3.055 1265
Fig. 3 e XRD patterns of Solid dispersions (SDs) of RPV
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and c correspond to SD's of RPV: RPVSD1, RPVSD2, RPVSD3 and
RPVSD4 respectively. FromFig. 3 it could be concluded that the
drug might have transferred to the amorphous state, as no
peaks were visible.
The DSC thermogram of RPV alone (Fig. 4) shows an
endothermic Tmax of 248.49 C, corresponding to the melting
point of the crystalline form of RPV. RPV melts with decom-
position which starts at about 248.49 C. In the DSC thermo-
grams of physical mixtures and solid dispersions of RPV with
Kollidan VA 64 the sharp melting point peak of pure RPV at
248.49 C was not visible (Fig. 5) in all the cases. The charac-
teristic features of the RPV peak were lost. This indicated that
RPV was molecularly dispersed and no longer present as a
crystalline material, but was converted into the amorphous
state.
Fig. 6 illustrates the FTIR spectra of RPV, physical mixture
and solid dispersions. The IR spectrum of RPV is characterized
by typical absorption bands at about 2217 cm1 (C^N),
1652 cm1 (C]O stretch), 1497 cm1 (aromatic nC ¼ C),
1435 cm1 (CeH bending), 1338 cm1(-CH wagging) and 1199
cm1(symmetric CeN stretching). Additional absorption
bands are observed at 1631 cm1, 1596 cm1, 1537 cm1,
1504 cm1, 1249 cm1, 1214 cm1, 1179 cm1, 1152 cm1 and
1070 cm1. There is a reduction of peak intensities is observed
in PMs and SDs and all other peaks of RPV were smoothened
indicating strong physical interaction of the drug with carrier
materials. However, no additional peaks were observed in any
of the binary systems, indicating absence of any chemical
interaction between RPV and the carriers.
Fig. 7 display SEM photographs for RPV physical mixtures
and Fig. 8 represents SEM micrographs of RPV and SDs. The
RPV crystals seemed to be irregular in shape and size. SEM
images of SD's clearly indicated the interaction of drug with
respective carriermaterial and concluded the incorporation of
drug in matrix material. While examining PMs no specific
interaction observed between drug and matrix material. In
case of SDs it was difficult to distinguish the presence of RPV
crystals. The RPV crystals appeared to be incorporated in the
matrix material. From SEM images it can be deduced that the: RPVSD1 (a), RPVSD2 (d), RPVSD3 (b), RPVSD4 (c).
Fig. 4 e DSC thermogram of Rilpivirine.
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vent evaporation method.
The aqueous solubility of RPV is found to be
0.0185 ± 0.0011 mg/mL which can be considered as practically
insoluble drug in water. The solubility of RPV increased
markedly in water in presence of matrix material. There was
an enhancement of 14.9 fold in solubility for RPVSD2 and for
RPVSD1, RPVSD3 and RPVSD4 it is about 5.9, 5.4 and 4.2 fold i.e.
the corresponding solubility values are 0.275 ± 0.045,
0.110 ± 0.009, 0.099 ± 0.002 and 0.078 ± 0.014 respectively. The
solubility of physical mixtures PM1, PM2, PM3 and PM4 was
found to be 0.027 ± 0.011, 0.025 ± 0.011, 0.035 ± 0.012 and
0.029 ± 0.014 mg/ml respectively which are greater than pure
drug but not significant increase as compared with SDs. The
enhancement in aqueous solubility of RPV SDs can be
explained in terms of wetting property and hydrophilicityFig. 5 e DSC curves of PMs of RPV: PM1 (a), PM2 (d), PM3 (b) and
RPVSD4 (f).nature of carriers with simultaneous reduction in the crys-
tallinity of the drug. All solid dispersion systems displayed
higher solubility of RPV than pure drug. Enhancement in sol-
ubility was observed in the following order: (Kollidan VA 64:
Gelucire 50/13)> (Kollidan VA 64)> (Kollidan VA 64: Lecithin
soya)> (Kollidan VA 64: Avicel PH-101).
The dissolution curves of RPV, RPV physical mixtures and
RPV solid dispersions in 0.5% Polysorbate 20 in 0.01 N HCl
(pH ¼ 2.0) at 37 ± 0.5 C are shown in Fig. 9 and the corre-
sponding values are tabulated in Table 2. From the obtained
results it is perceptible that all the binary systems of RPV have
superior dissolution rates than pure drug and its corre-
sponding physical mixtures. The physical mixtures also
showed improved dissolution rate as compared with RPV but
the highest drug release is observed for SDs prepared by sol-
vent evaporationmethod. It was observed thatmore than 85%
of the drug is released in 30 min though there are differences
in release mechanism in the initial 20 min. After 60 min
almost about 98% of the drug is released in all the cases. It is
evident that the solid dispersions improved the dissolution
rate of RPV to the greatest extent. Enhanced dissolution from
the solid dispersions is due to greater hydrophilicity and
higherwetting effectwhich increased the contact between the
drug and the carrier. The rapid dissolution of RPV from solid
dispersionsmay be attributed to a decrease in the crystallinity
of drug and its molecular and colloidal dispersion in the hy-
drophilic carrier matrix. As the soluble carrier dissolves, the
insoluble drug gets out in the open to dissolution medium in
the form of very fine particles for quick dissolution. The
dissolution profiles of RPV SDs were used to evaluate the ki-
netics of drug release. Six different kinetic models were
applied to understand the drug release characteristics. In
order to select the appropriate mathematical model to
describe drug release kinetics Coefficient of determination (R2)
and root-mean-square error (RMSE) were evaluated for modelPM4 (c) and SDs: RPVSD1 (e), RPVSD2 (g), RPVSD3 (h) and
Fig. 6 e FT-IR spectra of RPV (a), PMs of RPV : PM1 (b), PM2 (e), PM3 (c) and PM4 (d) and SDs: RPVSD1 (b1), RPVSD2 (d1), RPVSD3
(e1) and RPVSD4 (c1).
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(R2) to unity and smaller the value of root-mean-square error
(RMSE) we opt to choose that model as appropriate model
which best describes the drug release profile. Coefficient of
determination (R2) and root-mean-square error (RMSE) values
tabulated in Table 3 and used to select appropriate model that
describes drug release characteristics. From the obtained re-
sults it is observed that for RPVSD1, RPVSD3 and RPVSD4 drugFig. 7 e SEM micrographs of RPV physicarelease mechanism is best described by Weibull model for
which obtained Coefficient of determination values are 0.9312,
0.9774 and 0.9564 and root-mean-square error values are 3.8,
3.0 and 3.9 respectively. Since this is an empiric model, it
presents some deficiencies like there is no kinetic fundament
and could only describe, but does not adequately characterize
the dissolution kinetic properties of the drug and it is of
limited use for establishing in vivo in vitro correlations.l mixtures PM1, PM2, PM3 and PM4.
Fig. 8 e SEM micrographs for RPV (a), SDs: RPVSD1 (b), RPVSD2 (d), RPV RPVSD3 (e) and RPVSD4 (c).
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obtained Coefficient of determination and root-mean-square
error values are 0.9560 and 5.7 respectively. This model is a
semi-empirical model, relating exponentially the drug release
to the elapsed time. This model is used to analyse the release
of pharmaceutical polymeric dosage forms, when the release
mechanism is not well known or when more than one type of
release phenomena could be involved.
Dissolution efficiency (%DE) is the area under the dissolu-
tion curve between time point's t1 and t2 expressed as a per-
centage of the curve at maximum dissolution, y100, over the
same time period and is expressed by the following
expression:Fig. 9 e Dissolution profiles for RPV, Physical mixtures (PMs) of
in 0.01 N HCl (pH ¼ 2.0) at 37± 0.5 C stirred at 75 rpm (n ¼ 3).Dissolution efficiency ðDEÞ ¼
Z t2
t1
y:dt
y100 ðt2 t1Þ  100
DE values of RPVSD1, RPVSD2, RPVSD3 and RPVSD4 are
found to be 74.3, 73.8, 71.3 and 72.2 respectively. DE values are
related with the real amount of drug dissolved in the disso-
lution medium and thus, lead to a better extrapolative for
in vivo performance.
The solid dispersion systems prepared by solvent evapo-
rationmethod showed a greater extent of dissolution rate and
solubility as compared to pure drug and physical mixtures.
The increased solubility and dissolution rate may beRPV and RPV solid dispersions (SDs) in 0.5% Polysorbate 20
Table 3 e Model-dependent mathematical kinetic models for the evaluation of drug release mechanism of RPV solid
dispersions.
Kinetic Models Coefficient of determination (R2) Root-mean-square error (RMSE)
RPVSD1 RPVSD2 RPVSD3 RPVSD4 RPVSD1 RPVSD2 RPVSD3 RPVSD4
Zero order 0.7148 0.8582 0.7734 0.7573 11.9 7.9 11.5 12.9
First order 0.6640 0.8100 0.6982 0.6983 14.7 10.4 15.3 17.4
Second order 0.6065 0.7508 0.6176 0.6245 22.1 15.6 27.6 33.6
Korsmeyer-Peppas 0.8736 0.9560 0.8968 0.8952 10.2 5.7 10.2 11.9
Weibull 0.9312 0.8330 0.9774 0.9564 3.8 9.4 3.0 3.9
HixsoneCrowell 0.6822 0.8275 0.7247 0.7203 13.5 9.4 13.6 15.4
Table 2 e The dissolution time of RPV, RPV Physical mixtures and Rilpivirine solid dispersions in 0.5% Polysorbate 20 in
0.01 N HCl (pH ¼ 2.0) at 37 ± 0.5 C stirred at 75 rpm; mean ± s (n ¼ 3).
Time (min) Percentage of drug dissolved
RPV PM1 PM2 PM3 PM4 RPVSD1 RPVSD2 RPVSD3 RPVSD4
10 8.2 ± 3.1 28.7 ± 6.3 32.1 ± 5.4 24.6 ± 6.2 19.8 ± 5.5 40.0 ± 0.9 45.7 ± 1.2 34.2 ± 2.8 32.6 ± 1.9
20 18.9 ± 2.2 36.4 ± 4.3 36.8 ± 2.3 27.2 ± 5.0 29.0 ± 5.1 69.8 ± 1.7 64.9 ± 1.8 64.9 ± 2.1 61.5 ± 2.0
30 34.5 ± 2.9 44.5 ± 3.2 46.8 ± 3.2 40.0 ± 4.9 39.0 ± 4.2 94.2 ± 1.6 87.1 ± 1.8 90.2 ± 2.0 93.2 ± 2.3
45 43.1 ± 2.1 52.8 ± 4.4 54.2 ± 2.3 48.4 ± 4.2 47.5 ± 3.8 97.1 ± 0.8 98.8 ± 0.9 94.7 ± 1.5 98.8 ± 0.6
60 54.2 ± 1.9 67.2 ± 4.8 66.0 ± 1.9 53.7 ± 4.2 59.9 ± 3.2 97.1 ± 0.5 100.4 ± 0.8 98.1 ± 0.8 98.8 ± 0.7
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crystallinity of drug and molecular dispersion of the drug in
carrier matrix (Karavas et al., 2007). The insoluble drug in
carrier matrix when out in the open to dissolution media the
soluble drug carrier dissolves in media and the drug will make
contact with dissolution media as very fine particles which is
responsible for speedy dissolution. Other important factor
responsible for faster dissolution is increased amorphicity of
the drug in SDs which is confirmed by diffraction and thermal
studies. The surfactant property f polymer which results in
increased surface available for dissolution which is also
responsible for faster dissolution. While performing the
dissolution studies it was observed the pure drug is floating on
the media. As compared with pure drug little amount is
observed for physical mixtures and the SDs sink immediately.
Data Analysis Tools for scientific data analysis provided in
Microsoft excel is used for statistical evaluation of data. Sta-
tistical assessment of dissolution data of RPV and RPV SDs is
done by ANOVA: Single Factor. When compared the dissolu-
tion profile of RPV with RPV SDs it is found that the F value for
RPVSD1, RPVSD2, RPVSD3 and RPVSD4 is 13.799, 14.735, and
10.835 respectively which are well above the F critical value
5.318. The P-value of RPVSD1, RPVSD2, RPVSD3 and RPVSD4 is
0.0059, 0.0050, 0.011 and 0.014 respectively which reflects
these findings by being significantly smaller than 0.05. From
these findings we conclude that there is a significant differ-
ence between the groups and from ANOVA test we say that
RPV SDs outperforms RPV. Further comparison of drug release
is done by t-Test: Paired Two Sample for Means between RPV
and RPV SDs dissolution profiles. The absolute t Stat values for
RPVSD1, RPVSD2, RPVSD3 and RPVSD4 is found to be 9.131,
13.282, 8.017 and 6.968 respectively which are greater than t
Critical two-tail value 2.776. Hence we conclude from these
finding that there is significant difference between RPV and
RPV SDS. The formation of RPV SDs improved the dissolution
rate as compared with RPV.4. Conclusions
In the binary systems of rilpivirine prepared with different
hydrophilic carriers showed superior performance in
enhancing aqueous solubility and the dissolution of Rilpivir-
ine. XRD, FTIR and DSC studies of the binary systems of ril-
pivirine showed that the crystallinity of rilpivirine was
decreased to a greater extent in solid dispersions, which
markedly increased the aqueous solubility and dissolution
rate of rilpivirine. The main factors contributed for higher
solubility and release rate are such as increasedwetability and
conversion to amorphous state. The dissolution efficiency for
all the solid dispersions is greater than 70%. Thus, the study
provided a way to enhance solubility and understand the
release mechanism.r e f e r e n c e s
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